Oxford Asset Management LLP Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Oxford Asset Management LLP acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,420 shares of the biotechnology company’s stock, valued at approximately $230,000.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after purchasing an additional 80,302 shares in the last quarter. Geode Capital Management LLC boosted its position in ADMA Biologics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after buying an additional 50,399 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock valued at $80,065,000 after acquiring an additional 643,661 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock worth $64,654,000 after acquiring an additional 102,692 shares during the last quarter. Finally, Perpetual Ltd acquired a new position in shares of ADMA Biologics in the fourth quarter worth about $62,300,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $21.86 on Monday. The firm has a fifty day moving average of $18.80 and a two-hundred day moving average of $18.27. The firm has a market cap of $5.19 billion, a P/E ratio of 78.07 and a beta of 0.53. ADMA Biologics, Inc. has a 1-year low of $6.49 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.